AU2017211976B2 - Means and methods for staging, typing and treating a cancerous disease - Google Patents

Means and methods for staging, typing and treating a cancerous disease Download PDF

Info

Publication number
AU2017211976B2
AU2017211976B2 AU2017211976A AU2017211976A AU2017211976B2 AU 2017211976 B2 AU2017211976 B2 AU 2017211976B2 AU 2017211976 A AU2017211976 A AU 2017211976A AU 2017211976 A AU2017211976 A AU 2017211976A AU 2017211976 B2 AU2017211976 B2 AU 2017211976B2
Authority
AU
Australia
Prior art keywords
cells
cancer
dcc
dccs
somatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017211976A
Other languages
English (en)
Other versions
AU2017211976A1 (en
Inventor
Isabelle HODAK
Martin Hoffmann
Christoph Klein
Sebastian SCHEITLER
Melanie WERNER-KLEIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Regensburg
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Universitaet Regensburg
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Regensburg, Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Universitaet Regensburg
Publication of AU2017211976A1 publication Critical patent/AU2017211976A1/en
Application granted granted Critical
Publication of AU2017211976B2 publication Critical patent/AU2017211976B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2017211976A 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease Active AU2017211976B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease
EP16152883.1 2016-01-27
PCT/EP2017/051789 WO2017129753A1 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (2)

Publication Number Publication Date
AU2017211976A1 AU2017211976A1 (en) 2018-08-02
AU2017211976B2 true AU2017211976B2 (en) 2022-09-22

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017211976A Active AU2017211976B2 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Country Status (10)

Country Link
US (1) US11702701B2 (enExample)
EP (2) EP3199641B1 (enExample)
JP (1) JP2019508032A (enExample)
KR (1) KR20180102674A (enExample)
CN (1) CN108770360B (enExample)
AU (1) AU2017211976B2 (enExample)
CA (1) CA3012404A1 (enExample)
ES (1) ES2905208T3 (enExample)
SG (1) SG11201805990XA (enExample)
WO (1) WO2017129753A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673541B1 (en) 1998-09-18 2004-01-06 Micromet Ag DNA amplification of a single cell
WO2002037113A2 (en) * 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
ITRM20110149A1 (it) * 2011-03-25 2012-09-26 Massimo Zollo Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione.
WO2013009632A2 (en) * 2011-07-08 2013-01-17 The University Of Utah Research Foundation Methods of detecting hereditary cancer predisposition
EP3211099A1 (en) * 2011-12-10 2017-08-30 Abbott Molecular Inc. Materials and methods for diagnosis of malignant melanoma and prognosis of metastasis of malignant melanoma
WO2015023551A1 (en) * 2013-08-13 2015-02-19 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
US10273538B2 (en) 2014-02-05 2019-04-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Error-free sequencing of DNA

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARBST, K. et al., "Molecular and genetic diversity in the metastatic process of melanoma", 2014. J Pathol, Vol.233, No.1, pg. 39-50 *
PICARD, M. et al., "Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection", 2014. Br. J. Dermatol., Vol. 171, No. 1, pg. 108-114 *
SANBORN, J. Z. et al., "Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination", 2015. PNAS, Vol. 112, No. 35, pgs. 10995-11000. *
TRINH, V.A. & HWU, W.J., "Chemoprevention for Brain Metastases", 2011. Curr. Oncol. Rep., Vol.14, No.1, pg. 63-69 *
ULMER, A. et al., "Quantitative measurement of melanoma spread in sentinel lymph nodes and survival", 2014. PLOS Med, Vol. 11, No. 2, pg.1-17 *

Also Published As

Publication number Publication date
US11702701B2 (en) 2023-07-18
JP2019508032A (ja) 2019-03-28
AU2017211976A1 (en) 2018-08-02
CN108770360A (zh) 2018-11-06
EP3199641B1 (en) 2021-09-29
KR20180102674A (ko) 2018-09-17
CN108770360B (zh) 2022-06-14
WO2017129753A8 (en) 2017-10-19
EP3199641A1 (en) 2017-08-02
WO2017129753A1 (en) 2017-08-03
ES2905208T3 (es) 2022-04-07
SG11201805990XA (en) 2018-08-30
CA3012404A1 (en) 2017-08-03
US20190062845A1 (en) 2019-02-28
EP3408411A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
KR102149483B1 (ko) 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
TW201632629A (zh) 用於癌症診斷與預後的方法
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
CN109476698B (zh) 基于基因的炎性肠病诊断
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
KR20180049093A (ko) 신규한 바이오마커 및 암의 치료 방법
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
CN111405901A (zh) 含有miRNA的癌症治疗用医药组合物
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
CN108624683B (zh) Usp48基因突变在acth型垂体腺瘤分子诊断中的应用
CN115362255A (zh) 用无七之子2(sos2)抑制剂治疗眼科疾患
AU2017211976B2 (en) Means and methods for staging, typing and treating a cancerous disease
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
US20040138441A1 (en) Novel gene functionally related to dyslexia
US20090258344A1 (en) Methods for identifying risk of breast cancer and treatments thereof
KR102647919B1 (ko) App 돌연변이 세포 및 이의 이용
KR20050008644A (ko) 위암에서의 유전자 발현 프로파일
US20030219787A1 (en) Novel human gene functionally related to dyslexia
CN113718033A (zh) 生物标记物在制备用于预测结直肠癌患者预后的试剂中的应用
KR20130048240A (ko) Ｐｃｂｐ―１ 항원에 대한 모노클로날 항체, 및 그의 용도
CN116356008A (zh) 先天性心脏病相关setd2基因新发变异位点及其应用
CN117177739A (zh) 负载细胞外囊泡的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)